169 related articles for article (PubMed ID: 37324547)
1. Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.
Entzminger KC; Fleming JK; Entzminger PD; Espinosa LY; Samadi A; Hiramoto Y; Okumura SCJ; Maruyama T
Antib Ther; 2023 Apr; 6(2):108-118. PubMed ID: 37324547
[TBL] [Abstract][Full Text] [Related]
2. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.
Ju B; Fan Q; Liu C; Shen S; Wang M; Guo H; Zhou B; Ge X; Zhang Z
Cell Rep; 2023 Jun; 42(6):112532. PubMed ID: 37219999
[TBL] [Abstract][Full Text] [Related]
3. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
[TBL] [Abstract][Full Text] [Related]
4. Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.
Shah M; Woo HG
Front Mol Biosci; 2023; 10():1236617. PubMed ID: 37828918
[TBL] [Abstract][Full Text] [Related]
5. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
6. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
[TBL] [Abstract][Full Text] [Related]
7. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
[TBL] [Abstract][Full Text] [Related]
8. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
9. Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
bioRxiv; 2023 Jan; ():. PubMed ID: 36711991
[TBL] [Abstract][Full Text] [Related]
10. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
[TBL] [Abstract][Full Text] [Related]
11. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
bioRxiv; 2022 Dec; ():. PubMed ID: 36482971
[TBL] [Abstract][Full Text] [Related]
12. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
[TBL] [Abstract][Full Text] [Related]
13. XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants.
Jain S; Kumar S; Lai L; Linderman S; Malik AA; Ellis ML; Godbole S; Solis D; Sahoo MK; Bechnak K; Paredes I; Tanios R; Kazzi B; Dib SM; Litvack MB; Wimalasena ST; Ciric C; Rostad C; West R; Teng IT; Wang D; Edupuganti S; Kwong PD; Rouphael N; Pinsky BA; Douek DC; Wrammert J; Moreno A; Suthar MS
bioRxiv; 2024 Feb; ():. PubMed ID: 38370837
[TBL] [Abstract][Full Text] [Related]
14. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population.
Sutandhio S; Furukawa K; Kurahashi Y; Marini MI; Effendi GB; Hasegawa N; Ishimaru H; Nishimura M; Arii J; Mori Y
J Infect Public Health; 2023 Jul; 16(7):1064-1072. PubMed ID: 37196370
[TBL] [Abstract][Full Text] [Related]
15. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
[TBL] [Abstract][Full Text] [Related]
17. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.
Liu Y; Wang Z; Zhuang X; Zhang S; Chen Z; Zou Y; Sheng J; Li T; Tai W; Yu J; Wang Y; Zhang Z; Chen Y; Tong L; Yu X; Wu L; Chen D; Zhang R; Jin N; Shen W; Zhao J; Tian M; Wang X; Cheng G
Nat Commun; 2023 Apr; 14(1):2179. PubMed ID: 37069158
[TBL] [Abstract][Full Text] [Related]
18. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
[TBL] [Abstract][Full Text] [Related]
19. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
[TBL] [Abstract][Full Text] [Related]
20. Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants.
Popovic M
Microb Risk Anal; 2023 Apr; 23():100250. PubMed ID: 36777740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
